A 1-Year Cost-Effectiveness Model for the Treatment of Chronic Schizophrenia with Acute Exacerbations in Belgium
- 1 January 2000
- journal article
- Published by Elsevier in Value in Health
- Vol. 3 (1) , 1-11
- https://doi.org/10.1046/j.1524-4733.2000.31001.x
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- OlanzapinePharmacoEconomics, 1999
- Cost of Schizophrenia to UK SocietyPharmacoEconomics, 1999
- Olanzapine in practicePsychiatric Bulletin, 1998
- RisperidonePharmacoEconomics, 1998
- Computer ModellingPharmacoEconomics, 1998
- Cost Analysis of the Treatment of Schizophrenia in the UKPharmacoEconomics, 1998
- The Selection of Data Sources For Use in Modelling StudiesPharmacoEconomics, 1998
- Risperidone: An assessment of its economic benefits in the treatment of schizophreniaJournal of Medical Economics, 1998
- The Use of Consensus Methods and Expert Panels in Pharmacoeconomic StudiesPharmacoEconomics, 1997
- Some Aspects of the Cost of Schizophrenia in FrancePharmacoEconomics, 1997